Company registration number 09059325 (England and Wales)
APTAMER THERAPEUTICS LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
APTAMER THERAPEUTICS LIMITED
CONTENTS
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 9
APTAMER THERAPEUTICS LIMITED
STATEMENT OF FINANCIAL POSITION
- 1 -
2025
2024
Notes
£
£
£
£
Non-current assets
Property, plant and equipment
4
10,624
17,845
Current assets
Cash and cash equivalents
888
1,157
888
1,157
Current liabilities
5
(335,998)
(332,843)
Net current liabilities
(335,110)
(331,686)
Net liabilities
(324,486)
(313,841)
Equity
Called up share capital
8
1
1
Retained earnings
(324,487)
(313,842)
Total equity
(324,486)
(313,841)
The directors of the company have elected not to include a copy of the income statement within the financial statements.
For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 5 December 2025 and are signed on its behalf by:
Dr AC Tolley
Director
Company registration number 09059325 (England and Wales)
APTAMER THERAPEUTICS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2025
- 2 -
Share capital
Retained earnings
Total
£
£
£
Balance at 1 July 2023
1
(304,218)
(304,217)
Year ended 30 June 2024:
Loss and total comprehensive income
-
(9,624)
(9,624)
Balance at 30 June 2024
1
(313,842)
(313,841)
Year ended 30 June 2025:
Loss and total comprehensive income
-
(10,645)
(10,645)
Balance at 30 June 2025
1
(324,487)
(324,486)
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information
Aptamer Therapeutics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Windmill House, Innovation Way, York, YO10 5BR. The company's principal activities and nature of its operations are disclosed in the directors' report.
1.1
Accounting convention
The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS:
presentation of a statement of cash flows and related notes;
disclosure of the objectives, policies and processes for managing capital;
disclosure of key management personnel compensation;
disclosure of the future impact of new International Financial Reporting Standards in issue but not yet effective at the reporting date;
comparative narrative information;
for financial instruments and investment property measured at fair value and within the scope of IFRS 13, the valuation techniques and inputs used to measure fair value, the effect of fair value measurements with significant unobservable inputs on the result for the period and the impact of credit risk on the fair value; and
related party disclosures for transactions with the parent or wholly owned members of the group.
Revenue disclosures, including:
Disaggregated and total revenue from contracts with customers;
Explanation of significant changes in contract assets and liabilities;
Description of when performance obligations are satisfied, significant payment terms, and the nature of goods and services to be transferred;
Aggregate transaction price allocated to unsatisfied performance obligations and when revenue is expected to be recognised;
Significant judgements in determining the amount and timing of revenue recognition and the amount of capitalised costs to obtain or fulfil a contract;
Methods used to recognise revenue over time, determine transaction price and amounts allocated to performance obligations and determine amortisation of capitalised cost to obtain or fulfil a contract; and
Financial instrument disclosures, including:
Carrying amounts and fair values of financial instruments by category and information about the nature and extent of risks arising on financial instruments;
Income, expenses, gains, and losses on financial instruments.
The financial statements of the company are consolidated into the financial statements of Aptamer Group PLC. The consolidated financial statements of Aptamer Group PLC are available from its registered office, Windmill House, Innovation Way, York, England, YO10 5BR.
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -
1.2
Going concern
The Directors have considered the applicability of the going concern basis in the preparation of these financial statements, which includes assessing an internal forecast extending out to June 202true7 which is prepared at the Aptamer Group level. The Directors consider that this forecast represents a reasonable best estimate of the performance of the Group over the period to June 2027.
In July 2025, Aptamer Group PLC, the parent of which this company is a member ("The Group") completed a fundraise which raised gross proceeds of £2.0 million before expenses. The cash balance at the end of June 2025 was £1.1 million.
The Directors have assessed the going concern status on a Group basis, which includes this company. The accounts have therefore been prepared on a going concern basis, reflecting the ongoing support from the parent company. Further details of the going concern assessment can be found in the group financial statements for Aptamer Group Plc.
1.3
Property, plant and equipment
Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Property, plant and equipment
6 years on a straight-line basis
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income statement.
1.4
Impairment of tangible assets
At each reporting end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 5 -
1.5
Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.6
Financial assets
Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.
At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.
Financial assets at fair value through profit or loss
When any of the above-mentioned conditions for classification of financial assets is not met, a financial asset is classified as measured at fair value through profit or loss. Financial assets measured at fair value through profit or loss are recognized initially at fair value and any transaction costs are recognised in profit or loss when incurred. A gain or loss on a financial asset measured at fair value through profit or loss is recognised in profit or loss, and is included within finance income or finance costs in the statement of income for the reporting period in which it arises.
Financial assets held at amortised cost
Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.
Financial assets at fair value through other comprehensive income
Debt instruments are classified as financial assets measured at fair value through other comprehensive income where the financial assets are held within the company’s business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
A debt instrument measured at fair value through other comprehensive income is recognised initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognised through other comprehensive income are directly transferred to profit or loss when the debt instrument is derecognised.
The company has made an irrevocable election to recognize changes in fair value of investments in equity instruments through other comprehensive income, not through profit or loss. A gain or loss from fair value changes will be shown in other comprehensive income and will not be reclassified subsequently to profit or loss. Equity instruments measured at fair value through other comprehensive income are recognized initially at fair value plus transaction cost directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognized through other comprehensive income are directly transferred to retained earnings when the equity instrument is derecognized or its fair value substantially decreased. Dividends are recognized as finance income in profit or loss.
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 6 -
Impairment of financial assets
Financial assets carried at amortised cost and FVOCI are assessed for indicators of impairment at each reporting end date.
The expected credit losses associated with these assets are estimated on a forward-looking basis. A broad range of information is considered when assessing credit risk and measuring expected credit losses, including past events, current conditions, and reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity.
1.7
Financial liabilities
The company recognises financial debt when the company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.
Other financial liabilities
Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding.
Derecognition of financial liabilities
Financial liabilities are derecognised when, and only when, the company’s obligations are discharged, cancelled, or they expire.
1.8
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.9
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 7 -
Deferred tax
Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
2
Critical accounting estimates and judgements
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below.
Key sources of estimation uncertainty
Impairment of non-monetary assets
The company assesses non-monetary assets, and all other non-monetary assets including property, plant and equipment and right-of-use assets, for impairment on an annual basis by comparing the carrying value of the single cash-generating unit (“CGU”) with the recoverable amount, the recoverable amount being based on an assessment of the CGU’s value-in-use. The company uses discounted cashflows from the Aptamer Group's forecasts for the company's part of the CGU to determine the value-in-use.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Directors
2
2
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 8 -
4
Property, plant and equipment
Property, plant and equipment
£
Cost
At 1 July 2024
167,879
At 30 June 2025
167,879
Accumulated depreciation and impairment
At 1 July 2024
150,034
Charge for the year
7,221
At 30 June 2025
157,255
Carrying amount
At 30 June 2024
10,624
At 30 June 2023
17,845
5
Liabilities
2025
2024
Notes
£
£
Trade and other payables
6
335,998
332,843
6
Trade and other payables
2025
2024
£
£
Amount owed to parent undertaking
230,882
227,882
Amounts owed to fellow group undertakings
82,271
82,271
Accruals and deferred income
3,245
3,090
Other payables
19,600
19,600
335,998
332,843
APTAMER THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 9 -
7
Deferred taxation
ACAs
Tax losses
Total
£
£
£
Balance at 1 July 2023
6,267
(6,267)
Deferred tax movements in prior year
Charge/(credit) to profit or loss
(1,806)
1,806
Liability at 1 July 2024
4,461
(4,461)
Deferred tax movements in current year
Charge/(credit) to profit or loss
(1,805)
1,805
Liability at 30 June 2025
2,656
(2,656)
As at 30 June 2025, the company had unrelieved tax losses of approximately £179,000 (2024: £179,000). A deferred tax asset of £42,000 (2024: £40,000) has not been recognised in respect of these losses due to uncertainty of timing of taxable profits.
8
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary share of £1 each
1
1
1
1
The company’s Ordinary shares each carry the right to one vote at general meetings of the company. All issued share capital is classified as equity.
9
Related party transactions
The company has taken advantage of FRS 101 reduced disclosure framework which exempts disclosure of related party transactions made to wholly owned members of the Aptamer group.
Details of the balances outstanding with wholly owned group companies are given in note 6.
10
Immediate and ultimate parent company
The company is wholly owned by Aptamer Group PLC, a company registered in England and Wales.
The company’s ultimate parent and controlling party, Aptamer Group PLC. is both the largest and smallest entity for which group accounts are drawn up and copies of the consolidated financial statements are available from the registered office of Aptamer Group PLC, Windmill House, Innovation Way, York, England, YO10 5BR.
2025-06-302024-07-01Dr DHJ BunkaDr AC TolleyArron Craig TolleyfalsefalseCCH SoftwareiXBRL Review & Tag 2025.2090593252024-07-012025-06-30090593252025-06-30090593252024-06-3009059325core:PlantMachinery2025-06-3009059325core:PlantMachinery2024-06-3009059325core:ShareCapital2025-06-3009059325core:ShareCapital2024-06-3009059325core:RetainedEarningsAccumulatedLosses2025-06-3009059325core:RetainedEarningsAccumulatedLosses2024-06-30090593252023-06-3009059325bus:Director22024-07-012025-06-3009059325core:RetainedEarningsAccumulatedLosses2023-07-012024-06-3009059325core:RetainedEarningsAccumulatedLosses2024-07-012025-06-30090593252023-07-012024-06-3009059325core:PlantMachinery2024-06-3009059325core:PlantMachinery2024-07-012025-06-3009059325core:CurrentFinancialInstrumentscore:WithinOneYear2025-06-3009059325core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3009059325core:CurrentFinancialInstruments2025-06-3009059325core:CurrentFinancialInstruments2024-06-3009059325core:AcceleratedTaxDepreciationDeferredTax2023-06-3009059325core:TaxLossesCarry-forwardsDeferredTax2023-06-3009059325bus:PrivateLimitedCompanyLtd2024-07-012025-06-3009059325bus:FRS1012024-07-012025-06-3009059325bus:AuditExempt-NoAccountantsReport2024-07-012025-06-3009059325bus:Director12024-07-012025-06-3009059325bus:Director32024-07-012025-06-3009059325bus:SmallCompaniesRegimeForAccounts2024-07-012025-06-3009059325bus:FullAccounts2024-07-012025-06-30xbrli:purexbrli:sharesiso4217:GBP